Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shenzhen Chipscreen Biosciences CoSHSE:688321 +4.54%82 Net Current Asset Value is ¥0.15 as of Mar. 2026, which is 100% below its 10-year median of 34.58. GuruFocus rates SHSE:688321 with a GF Score™ of 82/100 and a GF Value™ of ¥37.51 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 606 Drug Manufacturers companies, Shenzhen Chipscreen Biosciences Co ranks worse than 99.34% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
The historical rank and industry rank for Shenzhen Chipscreen Biosciences Co's Net Current Asset Value or its related term are showing as below:
SHSE:688321'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 23.95 Med: 34.58 Max: 207.67
Current: 204.2
During the past 10 years, the highest Price-to-Net-Current-Asset-Value Ratio of Shenzhen Chipscreen Biosciences Co was 207.67. The lowest was 23.95. And the median was 34.58.
SHSE:688321's Price-to-Net-Current-Asset-Value is ranked worse than 99.34% of 606
companies
in the Drug Manufacturers industry
Industry Median: 5.895
vs SHSE:688321: 204.20
Shenzhen Chipscreen Biosciences Co (SHSE:688321) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Shenzhen Chipscreen Biosciences Co Net Current Asset Value Related Terms
Shenzhen Chipscreen Biosciences Co Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Chipscreen Biosciences Co Net Current Asset Value Chart
SHSE:688321 vs ZTS: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Chipscreen Biosciences Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Chipscreen Biosciences Co Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shenzhen Chipscreen Biosciences Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Shenzhen Chipscreen Biosciences Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ¥0.15 mean?
Shenzhen Chipscreen Biosciences Co (SHSE:688321) has a Net Current Asset Value of ¥0.15 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Shenzhen Chipscreen Biosciences Co and its competitors. This is 100% below median its historical median of 34.58. Over the past decade, Shenzhen Chipscreen Biosciences Co's Net Current Asset Value has ranged from 23.95 to 207.67. According to the industry distribution chart, Shenzhen Chipscreen Biosciences Co ranks #602 out of 606 companies in the Drug Manufacturers industry, placing it in the top 99.3%.
Is Shenzhen Chipscreen Biosciences Co's Net Current Asset Value too high?
Shenzhen Chipscreen Biosciences Co's current Net Current Asset Value of ¥0.15 is 100% below median its 10-year median of 34.58. Over the past 10 years, this metric has ranged from a low of 23.95 to a high of 207.67. Based on the distribution chart, Shenzhen Chipscreen Biosciences Co ranks #602 out of 606 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shenzhen Chipscreen Biosciences Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Chipscreen Biosciences Co's Net Current Asset Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhen Chipscreen Biosciences Co ranks #602 out of 606 companies for Net Current Asset Value. This places Shenzhen Chipscreen Biosciences Co in the lower half of its industry. The industry median Net Current Asset Value is 5.90. Historically, Shenzhen Chipscreen Biosciences Co's own Net Current Asset Value has ranged from 23.95 to 207.67 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.90, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Shenzhen Chipscreen Biosciences Co and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Chipscreen Biosciences Co's current Net Current Asset Value is ¥0.15, which is 100% below median its own 10-year median of 34.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Chipscreen Biosciences Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen Chipscreen Biosciences Co (SHSE:688321) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥37.51, compared to a current price of ¥30.63 — trading 18.3% below its estimated fair value. The current Net Current Asset Value is ¥0.15, which is 100% below median its 10-year median of 34.58. Shenzhen Chipscreen Biosciences Co's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Shenzhen Chipscreen Biosciences Co (SHSE:688321), the current Net Current Asset Value is ¥0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Chipscreen Biosciences Co (SHSE:688321) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Chipscreen Biosciences Co stock appears to be undervalued.
The current stock price of ¥30.63 is trading 18.3% below its estimated GF Value™ of ¥37.51.
GuruFocus considers Shenzhen Chipscreen Biosciences Co to be Modestly Undervalued.
Key valuation signals for SHSE:688321:
Net Current Asset Value: ¥0.15 (100% below median its 10-year median of 34.58)
GF Value™: ¥37.51 vs. price of ¥30.63 (18.3% below fair value)
No single metric tells the full story. See the SHSE:688321 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688321 has been successfully added to your 
